Acute Coronary Syndrome

Clinical Trial Finder

Many patients with acute coronary syndrome are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Duration of Dual Anti-Platelet Therapy (DUAL-ACS2)

Conditions:   Acute Coronary Syndrome;   Coronary Artery Disease
Interventions:   Other: 3 months dual anti-platelet therapy;   Other: 12 months dual anti-platelet therapy
Sponsors:   University of Edinburgh;   British Heart Foundation
Not yet recruiting - verified August 2017

Secondary PRevention Intervention by a Nursing Guide Program (SPRING)

Conditions:   Acute Coronary Syndrome;   Nutrition;   Physical Activity
Intervention:   Behavioral: INTERVENTION GROUP
Sponsor:   University Hospital A Coruña
Active, not recruiting - verified August 2017

GLOBAL LEADERS Adjudication Sub-Study

Conditions:   Coronary Artery Disease;   Platelet-aggregation Inhibitors
Intervention:  
Sponsors:   University Hospital Inselspital, Berne;   European Cardiovascular Research Center
Active, not recruiting - verified August 2017

Chinese Observational Prospective Study of Aging Population With Chronic Kidney Disease(C-OPTION)

Condition:   Chronic Kidney Disease
Intervention:  
Sponsors:   Chinese PLA General Hospital;   First Affiliated Hospital, Sun Yat-Sen University;   Fudan University;   China-Japan Friendship Hospital;   The First Affiliated Hospital of Dalian Medical University;   Shandong Provincial Hospital;   Beijing Friendship Hospital;   RenJi Hospital;   Hebei Medical University Third Hospital;   Second Hospital of Jilin University;   Renmin Hospital of Wuhan University
Not yet recruiting - verified August 2017

Validation of Chinese Version Appropriate Use Criteria for Coronary Revascularization

Conditions:   Appropriate Use Criteria;   Coronary Revascularization
Intervention:  
Sponsor:   China National Center for Cardiovascular Diseases
Recruiting - verified August 2017

Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France

Condition:   Atrial Fibrillation
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Vitamin K antagonists;   Drug: dabigatran (Pradaxa)
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified August 2017

Reducing Acute Coronary Syndrome Patient Delay

Condition:   Acute Coronary Syndrome
Interventions:   Behavioral: Text+Visual BCT-based intervention;   Behavioral: Text-only BCT intervention;   Behavioral: Leaflet information (control)
Sponsors:   Edinburgh Napier University;   University of Stirling;   University of Aberdeen;   University of Dundee;   The University of New South Wales
Recruiting - verified August 2017

NT-proBNP in the Management of Discharged Patients With Acutely Decompensated Heart Failure and Preserved Ejection Fraction

Conditions:   Heart Failure;   Preserved Left Ventricular Ejection Fraction
Intervention:   Other: NT-proBNP (Cardiac Biomarkers)
Sponsors:   Hospital Universitario Virgen de la Arrixaca;   Juan Cinca Cuscullola;   Pablo García Pavía;   Manuel Martinez Selles;   Antoni Bayés Genís;   Alfonso Varela Román;   Pedro Luis Sánchez Fernández
Recruiting - verified August 2017

The Physiological Impact of CTO PCI on Coronary Pressure Measurements and Correlation in Donor Vessel

Conditions:   Acute Coronary Syndrome;   Coronary Artery Disease
Intervention:  
Sponsor:   Basildon and Thurrock University Hospitals NHS Foundation Trust
Recruiting - verified August 2017

Early Endoscopy for Acute Upper Gastrointestinal Bleeding in Acute Coronary Syndrome Patients

Condition:   Gastrointestinal Bleeding
Intervention:   Other: endoscopic hemostasis
Sponsor:   Far Eastern Memorial Hospital
Recruiting - verified August 2017

Mild Therapeutic Hypothermia for Patients With Acute Coronary Syndrome and Cardiac Arrest Treated With PCI

Conditions:   Cardiac Arrest;   Acute Coronary Syndrome
Intervention:   Procedure: Mild Therapeutic Hypothermia (MHT)
Sponsor:   Jacek Kubica
Not yet recruiting - verified August 2017

"Me and My Heart" Study

Condition:   Acute Coronary Syndrome
Interventions:   Device: Active group with MEMS;   Device: Active group without MEMS;   Device: Control group with MEMS;   Device: Control group without MEMS
Sponsor:   AstraZeneca
Recruiting - verified August 2017

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified August 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified August 2017

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Condition:   Cost Sharing, Acute Coronary Syndrome
Intervention:   Other: Study voucher card
Sponsors:   AstraZeneca;   Duke Clinical Research Institute
Active, not recruiting - verified August 2017

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified August 2017

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified August 2017

The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry

Condition:   Platelet Aggregation Onhibitors
Intervention:   Drug: antiplatelet drugs - P2Y12 antagonists
Sponsor:   Faculty Hospital Kralovske Vinohrady
Recruiting - verified August 2017

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified August 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified August 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified August 2017

Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients

Condition:   Acute Myocardial Infarction
Intervention:   Drug: antiplatelet therapy
Sponsor:   Korea University Guro Hospital
Recruiting - verified August 2017

Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis

Conditions:   Aortocoronary Saphenous Vein Bypass Graft Atherosclerosis;   Intermediate Saphenous Vein Graft Lesions
Intervention:   Drug: extended-release niacin (Niaspan)
Sponsors:   North Texas Veterans Healthcare System;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified August 2017